文献速递痛风与晶体性关节病

2023年美国风湿病学会/欧洲抗风湿病联盟焦磷酸钙沉积病分类标准

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.
PubMed 文献 · Arthritis Rheumatol · 2023-07-26

美国风湿病学会(ACR)与欧洲抗风湿病联盟(EULAR)采用既定方法学制定了首部经验证的症状性焦磷酸钙沉积(CPPD)病分类标准。在关节痛、肿胀或压痛且症状不能完全由其他疾病解释的患者中,齿状突冠综合征或滑液中焦磷酸钙晶体可直接分类为CPPD病;否则采用加权评分>56分分类。推导队列敏感度92.2%、特异度87.9%,验证队列敏感度99.2%、特异度92.5%。

要点

  • 齿状突冠综合征或滑液焦磷酸钙晶体即可分类为CPPD病。
  • 无上述表现时,加权评分>56分可分类为CPPD病。
  • 推导队列敏感度92.2%、特异度87.9%,验证队列敏感度99.2%、特异度92.5%。

核心结论

  • 2023年ACR/EULAR CPPD病分类标准性能优异,将促进该领域研究。

研究设计与样本

  • 由ACR和EULAR支持的多国研究组遵循既定方法学制定分类标准,并在独立队列中验证。

主要发现

  • 推导队列含190例CPPD病例和148例模拟病例,敏感度92.2%、特异度87.9%。
  • 验证队列含251例CPPD病例和162例模拟病例,敏感度99.2%、特异度92.5%。

关键数值与推荐

  • 入选标准为关节痛、肿胀或压痛;排除标准为症状不能完全由其他疾病解释。
  • 齿状突冠综合征或滑液中焦磷酸钙晶体存在时,足以分类为CPPD病。
  • 无上述表现时,采用包含临床特征、相关代谢性疾病及实验室和影像学检查结果的加权标准,评分>56分可分类为CPPD病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first-ever validated classification criteria for symptomatic CPPD disease. METHODS: Supported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de-identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi-criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort. RESULTS: Among patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score >56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers). CONCLUSION: The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Abhishek A, Tedeschi SK, Pascart T, et al. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis Rheumatol. 2023. PMID: 37494275. doi:10.1002/art.42619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。